Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2022
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Societal CDMO
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.
Brand Name : AD101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Societal CDMO
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : AmyriAD
Deal Size : $1.0 million
Deal Type : Agreement
Details : Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).
Brand Name : AD101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 01, 2022
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : AmyriAD
Deal Size : $1.0 million
Deal Type : Agreement
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : CINECA
Deal Size : Undisclosed
Deal Type : Agreement
Details : This agreement covers the exchange of clinical and nonclinical trial information related to COVID-19 treatment using the repurposed Raloxifene molecule developed by five research organisations from the EU and South Korea.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 18, 2020
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : CINECA
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2020
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?